Company Overview and News
Nucor Corporation (NUE - Free Report) is set to release third-quarter 2018 results on Oct 18, before the opening bell. In the last reported quarter, the steel giant reported negative earnings surprise of 1.4% by posting adjusted earnings of $2.07 per share, which missed the Zacks Consensus Estimate of $2.10. Revenues went up roughly 24.9% year over year to $6,460.8 million, but lagged the Zacks Consensus Estimate of $6,492.
FTI.WI FMC NGVT NUE NGVT.WI CE
Over the past few years, lukewarm growth and sluggish inflation had removed basic materials from the list of investor favorites. However, this class of stocks has once again caught the imagination of investors. A spurt in inflation and the Trump administration’s policies has skewed the pitch in favor of domestic producers.
UFS BGEPF BG CE CLF
Chicago, IL – October 15, 2018 - Stocks in this week’s article include: Bristol-Myers Squibb Co. (BMY - Free Report) , Celanese Corp. (CE - Free Report) , Ternium S.A. (TX - Free Report) and Mettler-Toledo International Inc. (MTD - Free Report) .
WFC WFCNP VSH HEAR CE
PPG Industries Inc. (PPG - Free Report) is set to release third-quarter 2018 results ahead of the bell on Oct 18. Last quarter, the paint giant saw its profits from continuing operations drop roughly 25% year over year to $371 million or $1.51 per share. Adjusted earnings of $1.90 per share, however, beat the Zacks Consensus Estimate of $1.89, translating into a positive earnings surprise of 0.5%. Net sales went up roughly 9% year over year to $4,131 million, beating the Zacks Consensus Estimate of $4,118 million.
ALB PPG CE
2018-10-13 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GLBS PERY PSX LCII ABT CRM SHPG CSCO MS AMC COF-P SMPL ISRG SYF DVMT IDA JNJ HON.WI MSFT HLUKF LEVL FTCH APHQF UTHR MTW ADS FB SCL NFLX AXP SKX SU BAC COF-D COF-C COF-F AAPL CCI ELAN HUBB CE SU EB SURF TRIP PVTL GSK EOG SIX JPM PATK SBUX CNTTF KMRFZ CNC CNK WMT NKE SHAK AMZN HON KMI TWTR HCSG GSK TRMB EAF KMR AA DXC CVB EBAY REGN SLB BAC DFS CRON STBA SC UAL GOOGL LTXB AHBIF PENN SCL SLB QCOM WFCNP XLNX PM PG PNK CPB PYPL VMW WGO TLRY USB GS MYL JEC SWI XYF WEED DXC.WI ECL ABT IBM CWH WFC HON BUD C TPR CMCSA THO COF BSVN LECO CGC SNY VLTHF V SCHW HP T MRK SNE DPZ
Steel Dynamics, Inc. (STLD - Free Report) is set to release third-quarter 2018 results on Oct 17, after the closing bell. In the last reported quarter, the steel maker delivered a positive earnings surprise of 2.7% by posting earnings of $1.53 per share, which surpassed the Zacks Consensus Estimate of $1.49. Net sales went up around 29.3% year over year to roughly $3.1 billion, also beating the Zacks Consensus Estimate of $2.
STLD NGVT NGVT.WI CE
Celanese Corporation (CE - Free Report) entered into a definitive agreement to buy one of India’s largest domestic engineering thermoplastics (ETP) compounders — Next Polymers Ltd. Headquartered in Mumbai, Next Polymers specializes in custom compounding of several ETP materials with a compounding production facility of roughly 20 kilo tons per annum located in the Indian union territory of Dadra & Nagar Haveli.
CBSH CBSHP KMG CBCB CE MEOH
Earnings growth enthralls almost everyone, right from the top brass to research analysts. And why not? If a company doesn’t make money, it won’t last over the long haul. Consider a company’s revenues over a given period of time, subtract the cost of production and you have earnings.
CBSH CBSHP CBCB CE
Wall Street expects a year-over-year increase in earnings on higher revenues when Celanese (CE - Free Report) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
Tronox Limited (TROX - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 23% in the past one-month time frame.
CBSH TROXW TROXG CBSHP TROX CBCB SGH CE
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Cleveland-Cliffs Inc. (CLF - Free Report) declared that as of the close of business on Oct 5, it has redeemed the entirety of its outstanding 4.8% senior notes due October 2020 and 5.9% senior notes due March 2020. The total principal amount outstanding of debt redeemed was roughly $211 million. Per the company, these redemptions lowered annualized interest expense by roughly $10 million and expanded the company’s maturity profile.
CBT KMG CE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CE / Celanese Corp. on message board site Silicon Investor.
as of ET